On Thursday, Citizens JMP analysts reaffirmed their Market Outperform rating for Cidara Therapeutics stock (NASDAQ: NASDAQ: CDTX) with a price target of $47.00. Currently trading at $24.05, the stock ...

The rating follows discussions with Professor Florian Krammer from Mt. Sinai, who expressed optimism about Cidara’s CD388 antiviral candidate. According to InvestingPro data, analyst targets ...

Very few humans have gone up against bird flu. But we've all dealt with seasonal flu for years. Some of our immune systems might be primed to fend off a worse case, research finds.

FLORIAN KRAMMER: The preexisting immunity does very likely not protect us as a population from a new pandemic, but it might give us some protection against severe disease.

Very few humans have gone up against bird flu. But we've all dealt with seasonal flu for years. Some of our immune systems might be primed to fend off a worse case, research finds.

Very few humans have gone up against bird flu. But we've all dealt with seasonal flu for years. Some of our immune systems might be primed to fend off a worse case, research finds.

Very few humans have gone up against bird flu. But we've all dealt with seasonal flu for years. Some of our immune systems might be primed to fend off a worse case, research finds.

Very few humans have gone up against bird flu. But we've all dealt with seasonal flu for years. Some of our immune systems might be primed to fend off a worse case, research finds.

FLORIAN KRAMMER: The preexisting immunity does very likely not protect us as a population from a new pandemic, but it might give us some protection against severe disease.